Amyloid Biomarkers Study indicated the prevalence of abnormal Amyloid was about 10% higher than previously estimated among people with normal cognition.
The study included 19,000 people in 85 cohorts. The study observed that, in persons without dementia, the cerebrospinal fluid-based amyloid abnormality prevalence estimate that used data-driven cutoffs was 10% higher than the positron emission tomography-based prevalence estimate that used cohort-provided cutoffs.
Preclinical Alzheimer’s may be more prevalent than we think.
